Topline
Johnson & Johnson submitted data Friday to appeal for World Health Organization ‘s emergency use of its coronavirus vaccine, a move that would increase access to the single – dose pictures in lower – income countries and intermediate.
Puseletso Lesofe works on blood samples from people taking part in a COVID-19 vaccine test at the … [+]
PRESS ASSOCIATED
Key facts
An emergency use listing would clear the way for Johnson & Johnson to roll out the vaccine through the Covax campaign, an effort supported by WHO to gain insights into poor countries.
The campaign was launched in April and has been joined by 190 countries.
President Joe Biden is expected to announce $ 4 billion in donations to Covax, after the Trump administration refused to participate in the campaign.
Key background
Johnson & Johnson previously said the vaccine was less effective in some regions of the world including South Africa, where more widespread variations of Covid-19 have emerged in recent months. passed. However, the vaccine has been shown to be 66% effective overall in preventing moderate to severe cases of Covid-19 in clinical trials and 85% effective in preventing severe cases. No cases were reported in vaccine partners after day 49, the company noted.
Tangent
The Johnson & Johnson vaccine is currently under review by the Food & Drug Administration for emergency use in the U.S., where the federal government has already approved two-dose images from Moderna and Pfizer-BioNTech. The company applied for regulatory approval in the EU, which would make the fourth vaccine available to the bloc.
Quote Cruise
In January, Johnson & Johnson said they are also “studying immune responses to different doses and dosing regimens as well as examining a two-dose schedule of its COVID-19 vaccine candidate.”